Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker PRAX
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 5, 2026 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | Abigail P. Johnson | 2.57M | 9.2% | SCHEDULE 13G/A ↗ |
| Nov 5, 2026 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | FMR LLC | 2.57M | 9.2% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | Allan Gray Australia Pty Ltd | 3,108 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | Orbis Investment Management Ltd | 1.53M | 5.5% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G | PRAX Praxis Precision Medicines, Inc. | Felix J. Baker | 1.75M | 6.3% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | PRAX Praxis Precision Medicines, Inc. | Julian C. Baker | 1.75M | 6.3% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | PRAX Praxis Precision Medicines, Inc. | Baker Bros. Advisors (GP) LLC | 1.75M | 6.3% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G | PRAX Praxis Precision Medicines, Inc. | Baker Bros. Advisors LP | 1.75M | 6.3% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | Allan Gray Australia Pty Ltd | 4,067 | 0.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | Orbis Investment Management Ltd | 2.47M | 8.9% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | Steven A. Cohen | 65,933 | 0.2% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | 72 Investment Holdings, LLC | 65,933 | 0.2% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | Differentiated Ventures Investments, LLC | 65,933 | 0.2% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | Point72 Biotech Private Investments, LLC | 65,933 | 0.2% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | Point72 Capital Advisors, Inc. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | Point72 Asset Management, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| May 6, 2026 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | Abigail P. Johnson | 2.16M | 7.7% | SCHEDULE 13G/A ↗ |
| May 6, 2026 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | FMR LLC | 2.16M | 7.7% | SCHEDULE 13G/A ↗ |
| Apr 30, 2026 | SCHEDULE 13G | PRAX Praxis Precision Medicines, Inc. | Vanguard Capital Management | 1.42M | 5.1% | SCHEDULE 13G ↗ |
| Mar 27, 2026 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | The Vanguard Group | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | Perceptive Life Sciences Master Fund, Ltd. | 2.00M | 7.2% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | Joseph Edelman | 2.00M | 7.2% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | Perceptive Advisors LLC | 2.00M | 7.2% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G | PRAX Praxis Precision Medicines, Inc. | Allan Gray Australia Pty Ltd | 2,589 | 0.0% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13G | PRAX Praxis Precision Medicines, Inc. | Orbis Investment Management Ltd | 1.25M | 5.0% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | Steven A. Cohen | 1.57M | 6.1% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | 72 Investment Holdings, LLC | 65,933 | 0.3% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | Differentiated Ventures Investments, LLC | 65,933 | 0.3% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | Point72 Biotech Private Investments, LLC | 65,933 | 0.3% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | Point72 Capital Advisors, Inc. | 1.50M | 5.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | Point72 Asset Management, L.P. | 1.50M | 5.9% | SCHEDULE 13G/A ↗ |
| Feb 12, 2026 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | Phillip Gross | 965,313 | 3.8% | SCHEDULE 13G/A ↗ |
| Feb 12, 2026 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | Robert Atchinson | 965,313 | 3.8% | SCHEDULE 13G/A ↗ |
| Feb 12, 2026 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | Adage Capital Management, L.P. | 965,313 | 3.8% | SCHEDULE 13G/A ↗ |
| Feb 5, 2026 | SCHEDULE 13G | PRAX Praxis Precision Medicines, Inc. | Abigail P. Johnson | 1.35M | 5.4% | SCHEDULE 13G ↗ |
| Feb 5, 2026 | SCHEDULE 13G | PRAX Praxis Precision Medicines, Inc. | FMR LLC | 1.35M | 5.4% | SCHEDULE 13G ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | Janus Henderson Biotech Innovation Master Fund Ltd | 1.38M | 6.2% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | Janus Henderson Group PLC | 2.76M | 12.3% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | Bihua Chen | 1.00M | 4.0% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | Cormorant Asset Management, LP | 1.00M | 4.0% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | Steven A. Cohen | 2.07M | 9.6% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | 72 Investment Holdings, LLC | 65,933 | 0.3% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | Differentiated Ventures Investments, LLC | 65,933 | 0.3% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | Point72 Biotech Private Investments, LLC | 65,933 | 0.3% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | Point72 Capital Advisors, Inc. | 2.01M | 9.3% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | Point72 Asset Management, L.P. | 2.01M | 9.3% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | T. Rowe Price Associates, Inc. | 1.00M | 4.8% | SCHEDULE 13G/A ↗ |
| Nov 7, 2025 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | Morgan Stanley Capital Services LLC | 296,731 | 1.4% | SCHEDULE 13G/A ↗ |
| Nov 7, 2025 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | Morgan Stanley | 617,980 | 2.9% | SCHEDULE 13G/A ↗ |
| Nov 3, 2025 | SCHEDULE 13G/A (amended) | PRAX Praxis Precision Medicines, Inc. | Phillip Gross | 1.31M | 5.3% | SCHEDULE 13G/A ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 9:34 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances